Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Valuation & Earnings
This table compares Gain Therapeutics and Aldeyra Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 1,876.85 | -$20.41 million | ($0.61) | -4.00 |
| Aldeyra Therapeutics | N/A | N/A | -$55.85 million | ($0.73) | -5.73 |
Risk and Volatility
Gain Therapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Institutional & Insider Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Gain Therapeutics and Aldeyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -341.32% | -174.09% |
| Aldeyra Therapeutics | N/A | -72.25% | -47.92% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Gain Therapeutics and Aldeyra Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| Aldeyra Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Gain Therapeutics presently has a consensus target price of $8.67, indicating a potential upside of 255.19%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 127.27%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Gain Therapeutics is more favorable than Aldeyra Therapeutics.
Summary
Gain Therapeutics beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
